BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40

BioAge Labs, Inc.

BioAge Labs, Inc.

BIOA

0.00

BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ: BIOA) with a Buy rating and announces Price Target of $40.